Heparin binding protein in severe COVID-19-A prospective observational cohort study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
09
12
2020
accepted:
20
03
2021
entrez:
6
4
2021
pubmed:
7
4
2021
medline:
20
4
2021
Statut:
epublish
Résumé
Neutrophil-derived heparin binding protein (HBP; also known as azurocidin or CAP-37) is a key player in bacterial sepsis and a promising biomarker in severe infections. The aims of this study were to assess whether HBP is involved in the pathophysiology of COVID-19 and, if so, whether it can be used to predict severe disease preferably using a point-of-care test. This was a prospective convenience sample study of biomarkers in patients admitted to Skåne University hospital in Sweden with a confirmed COVID-19 diagnosis. Plasma samples and clinical data were collected within 72h after admission, during hospital stay and at discharge. Plasma HBP concentrations samples were measured both with enzyme-linked immunosorbent assay (ELISA) and with a novel dry immunofluorescence analyzer (Joinstar) point-of-care test. Thirty-five COVID-19 patients were enrolled in the study. Twenty-nine patients had blood samples taken within 72h after admission. We compared the highest HBP value taken within 72h after admission in patients who eventually developed organ dysfunction (n = 23) compared to those who did not (n = 6), and found that HBP was significantly elevated in those who developed organ dysfunction (25.0 ng/mL (interquartile range (IQR) 16.6-48.5) vs 10.6 ng/mL (IQR 4.8-21.7 ng/mL), p = 0.03). Point-of-care test measurements correlated well with ELISA measurements (R = 0.83). HBP measured by the POC device predicted development of COVID-induced organ dysfunction with an AUC of 0.88 (95% confidence interval (CI) 0.70-1.0). HBP is elevated prior to onset of organ dysfunction in patients with severe COVID-19 using a newly developed point-of-care test and hence HBP could be used in a clinical setting as a prognostic marker in COVID-19.
Sections du résumé
BACKGROUND AND AIMS
Neutrophil-derived heparin binding protein (HBP; also known as azurocidin or CAP-37) is a key player in bacterial sepsis and a promising biomarker in severe infections. The aims of this study were to assess whether HBP is involved in the pathophysiology of COVID-19 and, if so, whether it can be used to predict severe disease preferably using a point-of-care test.
METHODS
This was a prospective convenience sample study of biomarkers in patients admitted to Skåne University hospital in Sweden with a confirmed COVID-19 diagnosis. Plasma samples and clinical data were collected within 72h after admission, during hospital stay and at discharge. Plasma HBP concentrations samples were measured both with enzyme-linked immunosorbent assay (ELISA) and with a novel dry immunofluorescence analyzer (Joinstar) point-of-care test.
RESULTS
Thirty-five COVID-19 patients were enrolled in the study. Twenty-nine patients had blood samples taken within 72h after admission. We compared the highest HBP value taken within 72h after admission in patients who eventually developed organ dysfunction (n = 23) compared to those who did not (n = 6), and found that HBP was significantly elevated in those who developed organ dysfunction (25.0 ng/mL (interquartile range (IQR) 16.6-48.5) vs 10.6 ng/mL (IQR 4.8-21.7 ng/mL), p = 0.03). Point-of-care test measurements correlated well with ELISA measurements (R = 0.83). HBP measured by the POC device predicted development of COVID-induced organ dysfunction with an AUC of 0.88 (95% confidence interval (CI) 0.70-1.0).
CONCLUSIONS
HBP is elevated prior to onset of organ dysfunction in patients with severe COVID-19 using a newly developed point-of-care test and hence HBP could be used in a clinical setting as a prognostic marker in COVID-19.
Identifiants
pubmed: 33822821
doi: 10.1371/journal.pone.0249570
pii: PONE-D-20-37580
pmc: PMC8023466
doi:
Substances chimiques
AZU1 protein, human
0
Antimicrobial Cationic Peptides
0
Biomarkers
0
Blood Proteins
0
Types de publication
Clinical Trial
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0249570Déclaration de conflit d'intérêts
Adam Linder is listed as inventors on a patent on the use of HBP as a diagnostic tool in sepsis filed by Hansa Medical AB WO2008151808A1. This does not alter our adherence to PLOS ONE policies on sharing data and materials. All other authors have declared no relevant conflicts of interest.
Références
Clin Infect Dis. 2009 Oct 1;49(7):1044-50
pubmed: 19725785
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Med Hypotheses. 2020 Nov;144:110015
pubmed: 32592919
Crit Care Med. 2015 Nov;43(11):2378-86
pubmed: 26468696
J Intern Med. 2017 Jun;281(6):562-574
pubmed: 28370601
J Leukoc Biol. 2015 Oct;98(4):557-64
pubmed: 26160849
Intensive Care Med Exp. 2016 Dec;4(1):33
pubmed: 27704481
J Thromb Thrombolysis. 2020 Jul;50(1):72-81
pubmed: 32440883
Immunity. 2015 Mar 17;42(3):484-98
pubmed: 25746953
Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3
pubmed: 32320677
J Exp Med. 2020 Jun 1;217(6):
pubmed: 32302401
Clin Microbiol Infect. 2013 Dec;19(12):1122-8
pubmed: 23402373
Shock. 2017 Sep;48(3):313-320
pubmed: 28319494
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Eur J Clin Microbiol Infect Dis. 2021 Jan 29;:
pubmed: 33515095
Cell Mol Immunol. 2020 May;17(5):533-535
pubmed: 32203188
Eur Respir J. 2020 Jul 30;56(1):
pubmed: 32554538
JCI Insight. 2020 Jun 4;5(11):
pubmed: 32329756
Shock. 2019 Dec;52(6):e135-e145
pubmed: 30807529
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
EBioMedicine. 2020 May;55:102763
pubmed: 32361250